Alcohol Use Disorder: 5 Essential Clinical Insights
Evidence synthesis on naltrexone, acamprosate, gabapentin, topiramate, and disulfiram for primary care prescribers managing alcohol use disorder.
One-Minute Takeaway on Alcohol Use Disorder
One-Minute Takeaway
- Alcohol use disorder pharmacotherapy is strongly evidence-supported, with naltrexone (oral or extended-release injectable) showing the most consistent benefit on return to heavy drinking — meta-analytic NNT around 12.
- Acamprosate has comparable efficacy specifically for maintaining abstinence in patients who have already stopped drinking; thrice-daily dosing is its main practical limitation.
- Off-label gabapentin and topiramate carry moderate-quality randomized evidence; gabapentin shows particular benefit in patients with concurrent alcohol withdrawal symptoms.
- Disulfiram retains a narrow but real role in highly motivated patients with directly observed therapy and adequate social support.
- Despite USPSTF, APA, and VA/DoD endorsement, fewer than 4% of US adults with the diagnosis receive any pharmacotherapy — implementation, not evidence, is the rate-limiting step.
Why Alcohol Use Disorder Treatment Matters in Primary Care
Approximately 28 million US adults meet diagnostic criteria for alcohol use disorder in any given year, yet fewer than 10% receive any treatment, and fewer than 4% receive evidence-based pharmacotherapy. This gap persists despite USPSTF, American Psychiatric Association, and VA/DoD guidelines all endorsing first-line medications as part of routine alcohol use disorder management.
The treatment landscape includes three FDA-approved medications — naltrexone (oral and long-acting injectable), acamprosate, and disulfiram — and several effective off-label options including gabapentin and topiramate. All can be initiated by primary care prescribers without addiction specialist consultation, a fact poorly recognized in many practice settings.
For family physicians, alcohol use disorder represents one of the highest-yield chronic disease management opportunities. Brief intervention paired with pharmacotherapy modestly but consistently reduces drinking, improves quality of life, and lowers downstream healthcare utilization across cardiovascular, hepatic, and trauma-related outcomes.
The persistent prescribing gap reflects implementation barriers — clinician unfamiliarity, time constraints, persistent stigma, and historical over-medicalization of addiction as requiring specialist care — far more than evidence shortfalls. Pharmacotherapy decisions can be made and initiated within a routine visit by any licensed prescriber.
What Evidence Was Reviewed
This synthesis draws on the AHRQ comparative effectiveness review and Jonas 2014 JAMA meta-analysis covering more than 120 trials, two Cochrane systematic reviews on naltrexone and acamprosate, the COMBINE landmark RCT, the pivotal Mason 2014 and Anton 2020 trials of gabapentin, the Johnson 2007 topiramate trial, the Skinner disulfiram meta-analysis, and current US specialty society and government practice guidelines.
The table below summarizes the key evidence sources informing the comparative claims in this review.
| Study / Review | Design | n | Population | Intervention | Primary Outcome |
|---|---|---|---|---|---|
| Jonas 2014 (AHRQ) | SR / MA | ~22,800 across 122 trials | Outpatient AUD adults | Naltrexone, acamprosate, off-label agents vs placebo | Return to drinking, heavy drinking, NNT |
| COMBINE (Anton 2006) | RCT, 9-arm | 1,383 | DSM-IV alcohol dependence | Naltrexone, acamprosate, both, ± behavioral intervention | % days abstinent, time to 1st heavy drinking day |
| Maisel 2013 | MA | 64 trials | Alcohol use disorder | Naltrexone vs placebo; acamprosate vs placebo | Return to drinking, heavy drinking |
| Cochrane Naltrexone (Rösner 2010) | SR / MA | ~7,800 across 50 trials | Alcohol dependence | Naltrexone (oral + depot) | Return to any drinking, heavy drinking |
| Cochrane Acamprosate (Rösner 2010) | SR / MA | ~6,900 across 24 trials | Alcohol dependence | Acamprosate | Continuous abstinence |
| Mason 2014 | RCT, 3-arm | 150 | Alcohol-dependent outpatients | Gabapentin 900 vs 1800 vs placebo | Heavy drinking, complete abstinence |
| Anton 2020 | RCT | 96 | AUD with current withdrawal symptoms | Gabapentin titrated up to 1200 mg tid vs placebo | Total abstinence, no heavy drinking |
| Johnson 2007 | RCT | 371 | Alcohol dependence, currently drinking | Topiramate up to 300 mg/d vs placebo | % heavy drinking days |
| Skinner 2014 | MA | ~3,000 across 22 trials | Alcohol dependence | Disulfiram (open-label and blinded) | Drinking outcomes, abstinence |
| Garbutt 2005 | RCT, 3-arm | 624 | Alcohol dependence | Naltrexone XR 380 vs 190 mg vs placebo monthly | Heavy drinking events |
Key Findings on Alcohol Use Disorder Pharmacotherapy
Insight 1 — Naltrexone Reduces Return to Heavy Drinking
Among medications for alcohol use disorder, naltrexone has the most consistent and replicated evidence base. The Jonas 2014 AHRQ meta-analysis pooled 122 trials and reported a number needed to treat of approximately 12 to prevent one return to heavy drinking, with effect estimates broadly stable across populations and study contexts.
Mechanistically, naltrexone is a non-selective opioid antagonist that blunts the rewarding effects of alcohol, reducing both craving and the reinforcing experience of drinking. The COMBINE trial randomized 1,383 alcohol-dependent participants across nine arms and showed naltrexone added to medical management produced higher abstinence than medical management plus placebo.
Long-acting injectable naltrexone (380 mg IM monthly) provides an option for patients with adherence challenges. The Garbutt 2005 trial demonstrated efficacy versus placebo, with effects most pronounced in subgroups with several days of voluntary abstinence prior to the first injection.
Practical considerations include avoiding initiation in patients on opioid analgesics or with active opioid use disorder (precipitates withdrawal), monitoring transaminases (rare hepatotoxicity), and recognizing that naltrexone is effective whether the patient is fully abstinent at initiation or still drinking.
Insight 2 — Acamprosate Is Best Suited to Already-Abstinent Patients
Acamprosate has efficacy comparable to naltrexone for a different outcome — maintaining abstinence in patients who have already stopped drinking. The Cochrane review of 24 trials reported acamprosate reduces the risk of any drinking with NNT around 9, with particular benefit when initiation occurs after several days of abstinence.
The mechanism is incompletely understood but appears to involve modulation of NMDA glutamate and GABA neurotransmission, normalizing the protracted dysregulation seen in early abstinence. Onset of effect is gradual over weeks, fitting acamprosate’s role as a maintenance medication rather than an early-cessation tool.
Practical limitations include three-times-daily dosing (typically 666 mg three times daily, or 333 mg three times daily for renal impairment), which can challenge adherence, and renal elimination requiring dose adjustment in chronic kidney disease. Acamprosate is contraindicated in severe renal impairment (CrCl < 30 mL/min).
Of note, the COMBINE trial did not demonstrate acamprosate superiority over placebo in its overall comparison, raising questions about generalizability of European trial findings to US patient populations. The broader meta-analytic evidence base nonetheless continues to support efficacy.
Clinical pearl on alcohol use disorder pharmacotherapy choice: If the patient is still drinking and the goal is reduced heavy drinking, naltrexone is generally the better-aligned choice. If the patient has already achieved abstinence and the goal is maintaining it, acamprosate is at least equally reasonable and often better tolerated.
Insight 3 — Gabapentin and Topiramate Show Off-Label Efficacy
Among off-label medications for alcohol use disorder, gabapentin has the most robust contemporary evidence. Mason 2014 randomized 150 alcohol-dependent participants to gabapentin 900 mg, 1800 mg, or placebo daily for 12 weeks and reported the 1800 mg arm produced significantly higher rates of abstinence and no heavy drinking versus placebo, with dose-dependent benefit.
The Anton 2020 JAMA Internal Medicine trial extended this work, randomizing 96 participants with current alcohol withdrawal symptoms to gabapentin (titrated to 1200 mg three times daily) or placebo for 16 weeks. The trial demonstrated significantly higher rates of total abstinence and no heavy drinking with gabapentin, with the effect most pronounced in those reporting more pre-treatment withdrawal symptoms.
Topiramate has positive RCT evidence (Johnson 2007 in 371 alcohol-dependent participants) showing reductions in heavy drinking days. However, cognitive side effects — word-finding difficulty, paresthesias, concentration impairment — are common at therapeutic doses and limit real-world tolerability. Slow titration and target doses below 200 mg/day improve persistence on therapy.
Gabapentin and topiramate are reasonable considerations when first-line agents have not produced an adequate response, particularly in patients with concurrent insomnia, anxiety, or withdrawal symptoms (favoring gabapentin) or patients with weight concerns where topiramate’s modest weight-suppressing effect may be welcome.
Insight 4 — Disulfiram Retains a Narrow but Real Role
Disulfiram inhibits aldehyde dehydrogenase, causing an aversive reaction (flushing, nausea, hypotension) when alcohol is consumed. Real-world efficacy depends almost entirely on adherence: when taken under directly observed therapy, effect sizes are substantial; when self-administered, evidence of benefit is weak.
The Skinner 2014 meta-analysis distinguished open-label trials with monitoring (significant benefit) from blinded trials (modest or no benefit), reflecting the centrality of the patient’s expectation of the disulfiram-ethanol reaction to behavior change.
Disulfiram is best matched to highly motivated patients with stable social support that can implement directly observed dosing — most often a partner or family member. It is contraindicated in significant cardiovascular disease, hepatic impairment, and psychosis, and requires careful counseling about reactions to alcohol-containing products beyond beverages, including some mouthwashes, hand sanitizers, and topical preparations.
Insight 5 — Implementation, Not Evidence, Is the Bottleneck
Health system surveys consistently report fewer than 4% of US adults with alcohol use disorder receive evidence-based pharmacotherapy in any given year, despite all first-line agents being prescribable by primary care without addiction specialist referral.
The gap is not principally driven by patient refusal; surveys indicate substantial unmet demand for treatment when offered. Drivers include clinician unfamiliarity, time constraints, persistent stigma, and historical framing of addiction as requiring specialist care — none of which align with the current evidence base.
Implementation strategies that have demonstrably improved prescribing include EHR order sets paired with screening prompts, addiction-medicine ECHO programs, brief office workflows pairing AUDIT-C screening with same-visit prescribing, and quality metrics that count alcohol use disorder management alongside other chronic disease care.
Standard initiation involves obtaining baseline transaminases, confirming the patient is not on opioid analgesics or in active opioid use, and starting oral naltrexone at 50 mg daily (some clinicians begin at 25 mg for two days to assess tolerability).
- Oral 50 mg daily: First-line option; may be increased to 100 mg in selected patients.
- Long-acting injectable 380 mg IM monthly: Considered when adherence is the principal barrier; injections in the gluteal muscle by trained staff.
- Common adverse effects: Nausea, headache, fatigue, dizziness — usually transient.
- Hepatotoxicity: Rare but real; check transaminases at baseline and periodically.
- Opioid considerations: Counsel that naltrexone blocks opioid analgesia and warn about post-treatment opioid sensitivity reduction.
Treatment duration is typically a minimum of 3–6 months; longer maintenance is reasonable when benefit is observed.
Acamprosate works best when started after several days of alcohol abstinence. Standard dosing is 666 mg (two 333 mg tablets) three times daily, reduced to 333 mg three times daily if creatinine clearance is 30–50 mL/min.
The principal practical barrier is adherence to three-times-daily dosing across 12+ weeks of treatment. Strategies include:
- Pairing doses to existing meals.
- Pill organizers for the entire week’s supply.
- Smartphone reminders or family-member prompts.
- Shared decision-making upfront on whether the regimen fits the patient’s life.
Side effects are typically mild — diarrhea is most common, usually transient. Acamprosate has minimal drug-drug interactions and a benign metabolic profile, making it attractive for patients on multiple other medications.
The Anton 2020 protocol titrated gabapentin from 300 mg/day on day 1 to 1200 mg three times daily by day 4, sustained through 16 weeks. The Mason 2014 protocol used 1800 mg/day in three divided doses.
Practical considerations:
- Patients with current or recent alcohol withdrawal symptoms appear to derive the largest benefit.
- Gabapentin is renally cleared; dose-adjust in renal impairment.
- Sedation, dizziness, and edema are the most common adverse effects.
- Misuse potential, while smaller than for benzodiazepines or stimulants, is real — particularly in patients with concurrent opioid or polysubstance use disorders.
- Off-label use should be documented and discussed with the patient.
Treatment duration parallels other AUD medications — typically 12–16 weeks initially, with longer maintenance if effective.
The Johnson 2007 trial titrated topiramate from 25 mg/day to a target of 300 mg/day over 8 weeks. Many community clinicians now target 150–200 mg/day to balance efficacy with tolerability.
- Common adverse effects: Paresthesias, word-finding difficulty, fatigue, concentration impairment, weight loss, taste changes (notably for carbonated beverages).
- Slow titration: Increasing by 25–50 mg per week reduces dropout from cognitive effects.
- Renal stone risk: Inquire about prior stones; encourage hydration.
- Acidosis: Periodic bicarbonate monitoring with prolonged use.
- Pregnancy: Topiramate is associated with cleft palate risk and is not recommended in pregnancy.
Patients who tolerate topiramate often value its modest weight-loss effect, and this can support persistence.
Disulfiram is most appropriate for highly motivated patients who:
- Are alcohol-abstinent at initiation (no alcohol for at least 12 hours prior).
- Have stable social support able to implement directly observed therapy.
- Have no contraindications: significant cardiovascular disease, hepatic impairment, psychosis, or pregnancy.
- Understand the disulfiram-ethanol reaction mechanism and accept the risk-benefit trade-off.
Counseling points include avoidance of products containing ethanol — some mouthwashes, hand sanitizers, OTC cough syrups, certain topical preparations — and the persistence of the reaction for up to 14 days after discontinuation. Standard dosing is 250 mg daily, occasionally 500 mg in selected patients.
Quality & Consistency of Evidence on Alcohol Use Disorder Treatment
The evidence base for alcohol use disorder pharmacotherapy is unusually mature for a primary-care-managed chronic condition, with multiple large-scale meta-analyses converging on similar effect estimates. Consistency varies meaningfully across drugs and outcomes.
What the Evidence on Alcohol Use Disorder Treatment Does Not Show
Several specific gaps remain in the alcohol use disorder evidence base. Naming them clearly helps clinicians counsel patients honestly and prioritize implementation where evidence is strongest.
Specific Evidence Gaps
- Long-term outcomes beyond 12–24 weeks: Most trials end at this timeframe; data on 1- to 5-year sustained outcomes with continued or intermittent treatment are sparse.
- Direct comparative effectiveness: Head-to-head trials of naltrexone versus acamprosate, and of either versus off-label gabapentin or topiramate, are limited; choices rest on indirect comparisons and patient-context matching.
- Optimal first-line in patients still drinking versus already abstinent: Evidence supports broad framework but lacks randomized confirmation of the matching strategy in primary-care populations.
- Real-world adherence interventions: Strategies that bridge trial-level adherence (~70%) to primary-care adherence (often 30–50%) are not well characterized.
- Concurrent opioid use disorder: Patients on buprenorphine or methadone cannot use naltrexone; evidence-based AUD pharmacotherapy in this group leans heavily on acamprosate, gabapentin, or topiramate but is under-studied.
- Liver disease subgroups: Patients with cirrhosis or significant liver dysfunction were typically excluded; safe and effective regimens in this critical group remain understudied.
- Pregnancy: No first-line medication has adequate trial evidence in pregnancy; counseling and behavioral treatment dominate by default.
- Adolescent populations: Pharmacotherapy evidence in those under 18 is very limited; behavioral interventions remain first-line.
- Co-occurring psychiatric conditions: Major depression, PTSD, and bipolar disorder commonly co-occur with alcohol use disorder; integrated pharmacotherapy approaches lack adequate trial evidence.
Practical Implications
Based on the current evidence on alcohol use disorder pharmacotherapy, the following considerations may help structure prescribing decisions in family practice. These are framed as evidence-supported considerations rather than directive recommendations.
Evidence Supports Naltrexone as First-Line for Most Patients
Strongest meta-analytic evidence for reducing return to heavy drinking. Effective whether the patient is still drinking or recently abstinent. Long-acting injectable form offers an alternative when adherence is the principal concern.
Acamprosate Excels for Already-Abstinent Patients
Best initiated after several days of abstinence with a goal of maintaining it. Three-times-daily dosing is the principal practical limit; benign drug-interaction profile is an advantage in polypharmacy.
Gabapentin Shows Off-Label Benefit With Withdrawal Symptoms
Two well-designed RCTs support efficacy, with the largest effect in patients reporting current alcohol withdrawal symptoms. Reasonable second-line or first-line in selected patients with concurrent insomnia or anxiety.
Topiramate Reasonable Second-Line With Tolerability Trade-Off
Demonstrated reduction in heavy drinking days; cognitive side effects limit persistence. Slow titration and target doses below 200 mg/day improve real-world tolerability. Avoid in pregnancy.
Disulfiram Reserved for Selected Highly Motivated Patients
Effect depends almost entirely on adherence under directly observed therapy. Best matched to patients with stable social support and clear contraindication review.
Brief Intervention Amplifies All Pharmacotherapy
Brief counseling, motivational interviewing, and quitline integration produce additive effects across all alcohol use disorder medications. Even short structured advice during routine visits shifts outcomes.
Implementation Considerations
The most common alcohol use disorder pharmacotherapy pitfalls in primary care are not prescribing at all when treatment is indicated, undertreating with too-short courses, and failing to pair medication with even minimal behavioral support. A simple workflow — AUDIT-C at routine visits, brief intervention, same-visit prescribing where appropriate, follow-up at 2–4 weeks — closes most of the prescribing gap without requiring specialist referral.
Evidence Grade & Bottom Line
Overall Evidence Grade: STRONG for naltrexone reducing return to heavy drinking and for acamprosate maintaining abstinence — supported by multiple meta-analyses and Cochrane reviews. MODERATE for off-label gabapentin and topiramate based on positive RCTs with smaller samples. MODERATE for disulfiram contingent on directly observed therapy. STRONG evidence on the persistent prescribing gap in primary care.
Bottom Line
- Pharmacotherapy for alcohol use disorder is strongly evidence-based, primary-care-deliverable, and substantially underused; closing the prescribing gap is a high-yield clinical opportunity.
- Naltrexone is generally first-line for patients still drinking with a goal of reducing heavy drinking; acamprosate is a strong alternative for patients already abstinent who aim to maintain it.
- Off-label gabapentin has accumulating evidence and is particularly valuable in patients with concurrent withdrawal symptoms; topiramate is a reasonable option when its cognitive side-effect profile is acceptable.
- Disulfiram retains a narrow role limited primarily to highly motivated patients with directly observed therapy and adequate social support.
- All first-line medications can be initiated in routine primary care visits without addiction specialist referral, paired with brief behavioral support and short-interval follow-up.
Article Information & References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900. DOI: 10.1001/jama.2014.3628
- Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–2017. DOI: 10.1001/jama.295.17.2003
- Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–293. DOI: 10.1111/j.1360-0443.2012.04054.x
- Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867. DOI: 10.1002/14651858.CD001867.pub3
- Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332. DOI: 10.1002/14651858.CD004332.pub2
- Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70–77. DOI: 10.1001/jamainternmed.2013.11950
- Anton RF, Latham P, Voronin K, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180(5):728–736. DOI: 10.1001/jamainternmed.2020.0249
- Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641–1651. DOI: 10.1001/jama.298.14.1641
- Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366. DOI: 10.1371/journal.pone.0087366
- Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–1625. DOI: 10.1001/jama.293.13.1617
- US Preventive Services Task Force. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: USPSTF recommendation statement. JAMA. 2018;320(18):1899–1909. DOI: 10.1001/jama.2018.16789
- Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90. DOI: 10.1176/appi.ajp.2017.1750101
- Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–824. DOI: 10.1001/jama.2018.11406
- Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012;37(1):11–24. DOI: 10.1016/j.addbeh.2011.09.010
- SAMHSA. Medications for Substance Use Disorders. SAMHSA Publication No. PEP21-02-01-002. Rockville, MD: SAMHSA; 2021. DOI: 10.13140/RG.2.2.34201.66400